Nga Hong Si, Andrade Luis Gustavo Modelli, Contti Mariana Moraes, Valiatti Mariana Farina, Silva Maryanne Machado da, Takase Henrique Mochida
Universidade Estadual Paulista, Faculdade de Medicina de Botucatu, Departamento de Clínica Médica, Botucatu, SP, Brazil.
J Bras Nefrol. 2018 Apr-Jun;40(2):162-169. doi: 10.1590/2175-8239-JBN-3871. Epub 2018 Jun 4.
The progress in kidney transplantation has been evident over the years, as well as its benefits for patients.
To evaluate the 1.000 kidney transplants performed at the Botucatu Medical School University Hospital, subdividing the patients in different periods, according to the current immunosuppression, and evaluating the differences in graft and patient survival.
Retrospective cohort analysis of the transplants performed between 06/17/87 to 07/31/16, totaling 1,046 transplants, subdivided into four different periods: 1) 1987 to 2000: cyclosporine with azathioprine; 2) 2001 to 2006: cyclosporine with mycophenolate; 3) 2007 to 2014: tacrolimus with antimetabolic; and 4) 2015 to 2016: tacrolimus with antimetabolic, with increased use of the combination of tacrolimus and mTOR inhibitors.
There was an increase in the mean age of recipients and increase in deceased donors and their age in the last two periods. There was a reduction in graft function delay, being 54.3% in the fourth period, compared to 78.8% in the first, p = 0.002. We found a reduction in acute rejection, being 6.1% in the last period compared to 36.3% in the first, p = 0.001. Urological complications and diabetes after transplantation were more frequent in the first two periods. The rates of cytomegalovirus infection were higher in the last two periods. There was an improvement in graft survival, p = 0.003. There was no difference in patient survival, p = 0.77 (Figure 2).
There was a significant increase in the number of transplants, with evolution in graft survival, despite the worsening in the profiles of recipients and donors.
多年来肾移植取得了显著进展,对患者的益处也很明显。
评估在博图卡图医学院大学医院进行的1000例肾移植,根据当前的免疫抑制方案将患者分为不同时期,并评估移植物和患者生存率的差异。
对1987年6月17日至2016年7月31日期间进行的移植进行回顾性队列分析,共计1046例移植,分为四个不同时期:1)1987年至2000年:环孢素联合硫唑嘌呤;2)2001年至2006年:环孢素联合霉酚酸酯;3)2007年至2014年:他克莫司联合抗代谢药物;4)2015年至2016年:他克莫司联合抗代谢药物,且他克莫司与mTOR抑制剂联合使用增多。
在最后两个时期,受者的平均年龄增加,死亡供者及其年龄也增加。移植肾功能延迟有所减少,第四期为54.3%,而第一期为78.8%,p = 0.002。我们发现急性排斥反应有所减少,最后一期为6.1%,而第一期为36.3%,p = 0.001。前两个时期移植后泌尿系统并发症和糖尿病更为常见。最后两个时期巨细胞病毒感染率较高。移植物生存率有所提高,p = 0.003。患者生存率无差异,p = 0.77(图2)。
尽管受者和供者情况变差,但移植数量显著增加,移植物生存率有所提高。